Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tezepelumab in Allergic Bronchopulmonary Aspergillosis (ABPA)
NCT07757841Not yet recruiting
- Sponsor
- Shandong Provincial Qianfoshan Hospital
- Start
- Sep 2026
- Primary completion
- Jun 2027
- Countries
- 1
01
Overview
Open-label, single-arm trial of tezepelumab in allergic bronchopulmonary aspergillosis (ABPA) and severe asthma, sponsored by Shandong Provincial Qianfoshan Hospital. Primary endpoint: Number of steroid requiring exacerbations at 26 weeks. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
03
Conditions
allergic bronchopulmonary aspergillosis (ABPA)severe asthma
Beyond the preview
Go deeper on NCT07757841.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07757841.